Who are Chloroquine prophylaxis's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PF-06863135 + lenalidomide, Drug: Carfilzomib + Lenalidomide + Dexamethasone, ferrous gluconate with lactoferrin, Glatiramer acetate (GA), β-1,3/1,6-D-glucan, Peg-IFN + WB RBV for 24 weeks.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chloroquine-prophylaxis.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Chloroquine prophylaxis — Competitive Intelligence Brief

Chloroquine prophylaxis (Chloroquine prophylaxis) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial; immunomodulator. Area: Infectious Disease; Immunology.

marketed Antimalarial; immunomodulator Plasmodium falciparum heme detoxification pathway; toll-like receptors Infectious Disease; Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Chloroquine prophylaxis (Chloroquine prophylaxis) — Radboud University Medical Center. Chloroquine inhibits parasitic growth and modulates immune responses by accumulating in acidic compartments and interfering with parasite metabolism and host inflammatory pathways.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Chloroquine prophylaxis TARGET	Chloroquine prophylaxis	Radboud University Medical Center	marketed	Antimalarial; immunomodulator	Plasmodium falciparum heme detoxification pathway; toll-like receptors
PF-06863135 + lenalidomide	pf-06863135-lenalidomide	Pfizer	marketed	small molecule + immunomodulatory drug	unknown
Drug: Carfilzomib + Lenalidomide + Dexamethasone	Drug: Carfilzomib + Lenalidomide + Dexamethasone	Amgen	marketed	Proteasome inhibitor + Immunomodulatory agent + Corticosteroid combination	20S proteasome (carfilzomib); cereblon/CRBN (lenalidomide); glucocorticoid receptor (dexamethasone)
ferrous gluconate with lactoferrin	ferrous gluconate with lactoferrin	Ain Shams University	marketed	Iron supplement with immunomodulatory adjuvant
Glatiramer acetate (GA)	Glatiramer acetate (GA)	Teva Branded Pharmaceutical Products R&D, Inc.	marketed	Immunomodulator; disease-modifying therapy (DMT)
β-1,3/1,6-D-glucan	β-1,3/1,6-D-glucan	Al-Azhar University	marketed	Immunomodulator; biological response modifier	Dectin-1 (β-glucan receptor); Complement receptor 3 (CR3)
Peg-IFN + WB RBV for 24 weeks	Peg-IFN + WB RBV for 24 weeks	National Taiwan University Hospital	marketed	Immunomodulator + nucleoside analog antiviral combination	Interferon-alpha receptor (IFNAR); HCV RNA-dependent RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial; immunomodulator class)

Radboud University Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Chloroquine prophylaxis — Competitive Intelligence Brief. https://druglandscape.com/ci/chloroquine-prophylaxis. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab